GlaxoSmithKline is to sell the US rights to its antidepressant Wellbutrin XL (bupropion hydrochloride extended-release tablets) to Biovail for $510 million.
The move will help shake up GSK's US pharmaceutical business, which accounts for more than 40% of its total pharmaceutical business, but has been particularly hard hit by generic...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?